Cyclooxygenase gene therapy-inhalation - Aradigm/geneRx+

Drug Profile

Cyclooxygenase gene therapy-inhalation - Aradigm/geneRx+

Alternative Names: Pulmonary hypertension gene therapy

Latest Information Update: 19 Apr 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aradigm Corporation; geneRx+
  • Developer Aradigm Corporation
  • Class
  • Mechanism of Action Epoprostenol agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Pulmonary hypertension

Most Recent Events

  • 26 Sep 2002 Preclinical trials in Pulmonary hypertension in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top